
Tesamorelin is the most clinically-validated GHRH peptide — FDA-approved for reducing stubborn belly fat in HIV patients. It nudges the pituitary to release growth hormone naturally rather than replacing it directly.
A deeper look for the curious
For readers who want the full mechanism — feel free to skim.
Tesamorelin is a stable, long-lived version of GHRH — the brain signal that tells the pituitary to release growth hormone. A small chemical modification protects it from being broken down quickly. It's the only GHRH-type peptide with FDA approval — for reducing dangerous belly fat in HIV patients.
What researchers have observed in studies
FDA-approved for HIV-associated lipodystrophy — proven visceral fat reduction
Preserves natural GH pulsatility unlike GH injections
Increases IGF-1 within physiological range
Crosses blood-brain barrier — investigated for cognitive benefits
GHRH receptor (pituitary somatotrophs)
Stabilized 44 amino acid GHRH(1-44) analog
Amino acid chain
What scientists study this compound for
FDA-approved for reducing deep abdominal fat — the dangerous kind around organs.
Clinical trials show improvements in executive function and memory in older adults with mild cognitive impairment.
Researched for preserving muscle while reducing fat in aging populations.
Studied for reducing liver fat in people with HIV and metabolic syndrome.
Supports deeper sleep via natural GH pulses — similar to CJC-1295 but longer-validated clinically.
High-performance liquid chromatography confirms compound purity for every batch we produce.
ESI-MS verifies molecular weight and structural identity match the target compound.
Complete analytical data including chromatograms and mass spectra available per batch.
Laboratory use only. This product is sold for laboratory use and is not intended for human consumption or medical use.
Third-party verified. Typical purity ≥97%.